Biotechs Choosing Brazil For Drug Development And Early Sales
LATAM Provides A Significant Patient Population For Many Rare Conditions
Executive Summary
Brazil has established an accelerated pathway for approval of drugs for ultra-rare diseases, encouraging development activity – but the definition of qualifying drugs is narrow. Expansion to include more treatments could boost clinical trials activity and companies’ overall development presence.